• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Perfusion CT predicts survival for colorectal cancer patients

Article

Surgery may take care of initial disease for patients with colorectal cancer, but changes in blood flow in the liver can help predict whether residual disease will threaten the health of these patients later on -- even if no metastases are visible.

Surgery may take care of initial disease for patients with colorectal cancer, but changes in blood flow in the liver can help predict whether residual disease will threaten the health of these patients later on - even if no metastases are visible.

Researchers at Brighton and Sussex Medical School in the U.K. performed CT liver perfusion imaging for 88 patients who had undergone surgery to remove primary colon cancer. Among those, 51 had overt metastases visible in the liver, and 37 had none.

The protocol included a 50 mL bolus of contrast, followed by a series of images acquired every three seconds. The researchers noted the enhancement periods for the aorta, spleen and liver and made calculations to focus on the arterial phase of liver enhancement rather than portal.

Among 36 patients with no visible metastases who completed the study period, 12 had normal perfusion and 24 had an abnormal perfusion index. Patients in the first group had a 92% probability of survival at three years postsurgery, while those with abnormal perfusion had a 72% chance of survival. Among patients with visible metastases, survival was only 13.6% at three years.

"The survival is excellent if there are no metastases and normal perfusion," said lead author Dr. Kenneth Miles.

The progression of patients roughly corresponds with that associated with survival for Dukes' classification. Not all patients who show abnormal liver perfusion go on to develop liver metastases, Miles said. Some develop distant lesions.

"The question is what to do with patients who show this early abnormal blood flow," he said. "We're starting a protocol now to give them better imaging surveillance."

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.